Search Results for agency_names:"Justice Department"

Purisys, LLC has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of various controlled substances, including different forms of opium and marihuana extracts, for manufacturing purposes. The company aims to import these substances to create active pharmaceuticals and other controlled substances for its customers. Any comments or objections to this application must be submitted electronically by March 17, 2025. The approval for these imports will only be granted if the business activities align with legal requirements, and the import of finished dosage forms for commercial sale is not authorized.

In the Federal Register notice titled "Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order," the DEA sought to revoke Dr. Ibrahim Al-Qawaqneh's registration due to his exclusion from federal health care programs after pleading nolo contendere to a charge of offering unlawful Medi-Cal remuneration. Despite being given a chance to defend himself, the DEA found that Dr. Al-Qawaqneh failed to take full responsibility for his actions, which led to doubts about his trustworthiness. Consequently, his DEA Certificate of Registration was revoked to ensure compliance with laws regulating controlled substances.

The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), under the Department of Justice, is looking to gather public comments on a new information collection form called the Reciprocity Questionnaire (ATF Form 8620.59). This form aims to check if a job candidate has already completed a background investigation or polygraph with another federal agency. About 2,000 respondents are expected to fill out this form each year, taking around 10 minutes each to complete it. Public comments on the collection are welcome until March 24, 2021, and should cover the necessity, accuracy, enhancement, or burden of the proposed collection.

The Drug Enforcement Administration (DEA) received an application from Baxter Research Lab to register as a bulk manufacturer of marihuana, a Schedule I controlled substance. This registration would allow Baxter to produce large quantities of active pharmaceutical ingredients (APIs) for research purposes. The DEA will review the application to ensure all legal and safety measures are in place to prevent misuse. Comments or objections regarding this application can be submitted electronically until May 27, 2025.

Veranova, L.P. has applied to the Drug Enforcement Administration (DEA) to become an importer of specific controlled substances. These substances include Coca Leaves, raw Opium, Poppy Straw Concentrate, Thebaine, Noroxymorphone, and Fentanyl. The company intends to use these materials to manufacture active pharmaceutical ingredients and reference standards for testing purposes. The DEA invites public comments or objections by March 17, 2025, and requests for a hearing must be sent to the designated DEA addresses.

The Drug Enforcement Administration (DEA) decided to revoke the DEA Certificate of Registration for Dr. Willard J. Davis, a doctor in Texas, because he lost his state license to practice medicine, which means he can no longer handle controlled substances legally in Texas. The Texas Medical Board suspended Dr. Davis's medical license on May 16, 2024, and it remained suspended at the time of the decision. Since having a valid state medical license is necessary to maintain DEA registration for dispensing controlled substances, his registration was revoked, and any pending applications related to the registration were denied. This decision will be effective starting April 28, 2025.

Siemens Healthcare Diagnostics Inc. has submitted an application to the Drug Enforcement Administration to become a bulk manufacturer of certain controlled substances. The company intends to use these substances to produce products that are exempt from DEA regulations. Individuals or existing registered manufacturers can express their support or objections in writing by March 15, 2021, or request a hearing regarding this application by the same date.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Dr. Kevin Petersen, meaning he can no longer prescribe or handle controlled substances. This decision came after it was found that his medical license in Nevada, where he practiced, had expired and was then revoked, which automatically made him ineligible to maintain his DEA registration for handling such substances. Dr. Petersen did not contest this action by requesting a hearing, leading the DEA to proceed with its final decision. This order will officially take effect on January 29, 2025.

The R Consortium, Inc. has updated its membership by adding the Stiftung für Qualitätssicherung und Transparenz im Gesundheitswesen based in Berlin, Germany. This notification was filed as part of the requirements of the National Cooperative Research and Production Act of 1993, which helps limit the damages antitrust plaintiffs can recover under certain conditions. Membership is open, and the R Consortium intends to continue updating the authorities on any changes. The latest notification prior to this was submitted on October 1, 2020.

The National Armaments Consortium (NAC) has submitted new notifications about changes in its membership as required by the National Cooperative Research and Production Act of 1993. This filing aims to limit the damages that antitrust plaintiffs might claim under certain circumstances. The newly added members include companies from various states, such as Air Space Intelligence Federal Inc. and EverGlade Consulting, LLC. Despite these changes, the group's activity plan remains the same, and membership is still open. The Department of Justice published a related notice in the Federal Register on February 28, 2025.